Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine Combination Study in AML and MDS
NCT01211457Phase 2Unknown
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Jun 2010
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sapacitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Cyclacel Pharmaceuticals, Inc.. Status: unknown.
02
Drugs
sapacitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01211457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211457.